Stockreport

REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor ...

Elevai Labs, Inc.  (ELAB) 
PDF Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonistsElevai Bio [Read more]